secwatch.observer — SEC 8-K summary
======================================

Issuer:     Armata Pharmaceuticals, Inc. (ARMP)
CIK:        0000921114
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001104659-25-110351
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Armata Q3 loss from ops $7.8M; AP-SA02 Phase 2a shows efficacy, cGMP facility commissioned
--------------------------------------------------------------------------------

- Q3 2025 grant revenue $1.2M (vs $3.0M prior year); R&D expense $5.8M (vs $9.5M).
- Loss from operations $7.8M (vs $9.8M prior year); cash $14.8M as of Sep 30, 2025.
- Phase 2a diSArm study: AP-SA02 + BAT had higher cure rate at day 12 vs BAT alone; 100% response without relapse.
- 56,000 sq ft cGMP manufacturing facility in Los Angeles fully commissioned; enables scale-up for late-stage trials.
- Entered $15M secured credit agreement with Innoviva subsidiary, maturing January 2029, to fund AP-SA02 development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921114/000110465925110351/0001104659-25-110351-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921114/000110465925110351/armp-20251112x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-110351

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer